The Makary Resignation and the Media’s Nicotine Blind Spot

The coverage of Marty Makary’s resignation tells us as much about modern media incentives as it does about vaping policy.

Within hours, a familiar narrative solidified across major outlets. Donald Trump had allegedly met tobacco and vaping executives at a golf course. Trump wanted flavored vapes approved. Makary resisted. Trump pushed harder. Makary lost. End of story.

It was irresistible political theater: cigar smoke, golf carts, industry lobbyists, impulsive presidential dealmaking, and a regulator supposedly standing athwart corruption.

For much of the media, that was enough.

What was remarkable was not merely what reporters emphasized, but what they omitted.

Readers were repeatedly told that Makary had stood up to political pressure over flavored vaping products (Reuters 2026; Washington Post 2026; Guardian 2026). But they were rarely told that youth vaping rates have collapsed in recent years according to the CDC’s own data (FDA 2026a). They were rarely told that youth smoking has also continued its historic decline during the vaping era (CDC 2025). And they were almost never told that parts of the FDA’s own scientific review apparatus reportedly favored authorization of at least some flavored products because of their potential benefits for adult smokers trying to quit cigarettes (STAT 2026).

In other words, the dominant narrative was political. The scientific dispute itself was largely sidelined.

This matters because one can simultaneously believe two things: first, that political influence from industry or the White House is undesirable; and second, that Makary’s policy position may nevertheless have been scientifically flawed.

But nuance performs poorly in modern media ecosystems.

The preferred framing was simple: Trump pressured the FDA after chatting with industry figures at a golf course. That image alone carried enormous narrative weight. It fit perfectly into the broader press conception of Trumpian governance: informal, transactional, personality-driven, and favorable to friends and donors (Reuters 2026; New York Post 2026).

Yet almost no comparable scrutiny was applied to Makary’s own politics.

And make no mistake: ignoring data is political.

By the time of the resignation fight, the CDC’s National Youth Tobacco Survey showed youth vaping prevalence had fallen dramatically from its peak. Federal agencies themselves described youth e-cigarette use as being at the “lowest level in a decade” (FDA 2026a). Meanwhile, combustible cigarette smoking among American adolescents had fallen to historically unprecedented lows (CDC 2025).

Those are not trivial datapoints. They are central to the entire public-health argument.

If youth vaping is collapsing while cigarette smoking also remains extremely low, then the regulatory calculus changes. A policymaker must increasingly weigh the benefits of harm reduction for adults against a shrinking — though still real — youth risk problem.

That is precisely the debate many media reports avoided.

Instead, coverage often treated any support for flavored vaping products as self-evidently corrupt or anti-scientific. The possibility that flavored noncombustible nicotine products might help displace cigarettes — the deadliest legal consumer product in history — was frequently reduced to a passing sentence or omitted entirely (Vox 2026; Guardian 2026).

This is not accidental. Modern health journalism increasingly operates inside a narrow moral framework. Certain conclusions are socially approved; others are treated as suspect regardless of the evidence supporting them.

Over the past decade, Bloomberg-funded advocacy networks, activist public-health groups, and sections of the medical press have helped create an informational environment in which skepticism toward vaping restrictions is often portrayed not as a scientific disagreement but as evidence of industry capture.

The irony is profound.

Many journalists aggressively framed Trump as compromised by relationships with tobacco or vaping executives while showing little curiosity about ideological or philanthropic capture inside public health itself. Few asked why so many reporters reflexively adopted anti-vaping assumptions even as countries such as Sweden and New Zealand increasingly pointed toward harm reduction as a viable route away from smoking-related disease (Bates 2024; Public Health Agency of Sweden 2024).

Nor did many ask why FDA reviewers who reportedly supported some flavored product authorizations received so little attention. If the approvals were merely corrupt political gifts to industry allies, why were scientists inside the system supporting them at all?

The answer, of course, is that the science is contested. Public health involves tradeoffs. Nicotine is addictive. Youth uptake matters. Corporate influence matters. But so do adult smokers, comparative risk, behavioral substitution, and real-world epidemiology.

The media increasingly struggles to hold these competing truths simultaneously.

Instead, stories are often filtered through tribal political lenses. Trump pressures regulator: bad. Regulator resists Trump: good. Once that framework crystallizes, inconvenient data recedes into the background.

Ironically, this very dynamic may explain why Makary ultimately lost his position.

The administration appears to have concluded that Makary was not merely following science but selectively using it. From the White House perspective, he may have looked like a regulator ignoring improving youth data, disregarding harm-reduction evidence, frustrating industry expectations, and advancing his own policy preferences under the guise of neutrality.

That too is politics.

The deeper problem is not that politics entered the vaping debate. Politics always enters major regulatory decisions. The problem is that many journalists pretend politics only exists when it comes from the “wrong” people.

A golf-course conversation with industry executives is treated as scandalous political influence. Quiet ideological alignment between regulators, activist NGOs, philanthropic funders, media organizations, and public-health institutions is treated as objective expertise.

But both shape policy.

And when media outlets systematically omit evidence that complicates preferred narratives, bad policy becomes more likely. Regulators become less accountable, not more. Scientific uncertainty is flattened into moral certainty. Public trust erodes further.

The solution is not to hand the vaping industry unrestricted power, nor to pretend that Trumpian improvisation is an ideal regulatory model.

The solution is to insist that policymakers confront the full evidence base honestly — including evidence that disrupts established narratives.

If Makary ignored important epidemiological trends and sidelined evidence supporting harm reduction, then criticism is warranted. If Trump pressured the FDA through personal relationships, that deserves scrutiny too.

But journalism that only examines one form of influence while ignoring another is not independent journalism. It is narrative management.

And narrative management, however well intentioned, rarely produces good public health policy.

References

Bates, C. (2024) The case for tobacco harm reduction. London: Counterfactual.

CDC (2025) National Youth Tobacco Survey: Tobacco Product Use Among Middle and High School Students. Atlanta: Centers for Disease Control and Prevention.

FDA (2026a) ‘Youth e-cigarette use drops to lowest level in a decade’, U.S. Food and Drug Administration Press Release, 12 February.

Guardian (2026) ‘Makary resigns after clash with Trump administration over vaping approvals’, The Guardian, 13 May.

New York Post (2026) ‘Knives out for FDA chief Marty Makary after flavored vape fight’, New York Post, 7 May.

Public Health Agency of Sweden (2024) Smoking prevalence and nicotine use trends in Sweden. Stockholm: Folkhälsomyndigheten.

Reuters (2026) ‘FDA Commissioner Marty Makary resigns amid White House tensions over vape policy’, Reuters, 12 May.

STAT (2026) ‘FDA insiders divided over flavored vape approvals as Makary exits’, STAT News, 11 May.

Vox (2026) ‘Why Trump’s vape push alarmed public health experts’, Vox, 12 May.

Washington Post (2026) ‘FDA chief plans resignation amid turmoil over vaping decisions’, Washington Post, 12 May.